Profound Medical (PROF) Stock Price, News & Analysis

Company Overview

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia. The system features a closed-loop control mechanism that precisely adjusts ultrasound energy delivery based on continuous feedback from MR temperature mapping, enabling controlled ablation of prostate tissue while preserving surrounding structures.

Founded in 2015, Profound Medical has secured regulatory approvals and clearances in multiple jurisdictions, including CE mark certification for the European market and FDA clearance in the United States. The company has established a network of clinical partners and distributors across North America and Europe, where its technology is being adopted in leading cancer centers and urology clinics.

Profound Medical’s leadership comprises professionals with extensive experience in medical device development, clinical operations and regulatory affairs. The company continues to invest in research and development to expand its ultrasound platform for additional therapeutic indications and to support ongoing clinical studies aimed at improving patient outcomes.

Key Stats

• Today's Range: $6.59 to $6.90
• 50-Day Range: $5.95 to $7.27
• 52-Week Range: $3.76 to $8.95
• Volume: 88,508 shs
• Average Volume: 58,795 shs
• Market Capitalization: $249.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Hold

Profound Medical Stock Analysis - MarketRank™

Profound Medical scored higher than 23% of companies evaluated by MarketBeat, and ranked 759th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Profound Medical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Profound Medical has a consensus price target of $12.00, representing about 74.7% upside from its current price of $6.87.

Amount of Analyst Coverage

Profound Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Profound Medical are expected to grow in the coming year, from ($0.88) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Profound Medical is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Profound Medical is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Profound Medical has a P/B Ratio of 3.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.16% of the float of Profound Medical has been sold short.

Short Interest Ratio / Days to Cover

Profound Medical has a short interest ratio ("days to cover") of 41.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Profound Medical has recently increased by 0.80%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Profound Medical does not currently pay a dividend.

Dividend Growth

Profound Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for PROF on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Profound Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.52% of the stock of Profound Medical is held by insiders.

Percentage Held by Institutions

47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/20/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PROF
• CIK: 1628808
• Web: www.profoundmedical.com
• Phone: (647) 476-1350
• Fax: 64-7847-3739
• Employees: 150
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Profound Medical: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +74.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.57 million
• Net Margins: -206.76%
• Pretax Margin: -205.50%
• Return on Equity: -78.88%
• Return on Assets: -64.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.56
• Quick Ratio: 5.71

Sales & Book Value

• Annual Sales: $16.10 million
• Price / Sales: 15.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 3.75

Miscellaneous

• Outstanding Shares: 36,340,000
• Free Float: 35,786,000
• Market Cap: $249.66 million
• Optionable: Optionable
• Beta: 0.72